Microfluidic Device Systems Market in North America to Grow at Striking 21.70% CAGR from 2013 to 2019

There has been a recent release of a new report on the global microfluidic device systems market by Transparency Market Research (TMR). The report suggests that the global microfluidic device market is estimated to grow at a CAGR of 22.8% during the period of 2013 to 2019. The market, which was valued at US$1.5 bn in 2013, will reach US$5.2 bn in 2019.The report, which is titled “Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” provides a comprehensive study on the analysis of the microfluidic device market for the period from 2014 to 2019, wherein 2013 is considered as the base year for calculation. The report contains data related to the current market dynamics, trends, market drivers, restraints, and also the strategic developments propelling the global microfluidic device systems market.

The report states that the rising demand for microfluidic devices in proteomics and genomics, point of care testing, and miniaturization of chips are the chief driving forces behind the microfluidic device systems market’s growth. Another factor that could fuel the growth of the microfluidic device systems market is a change in the material mix, which would provide an opportunity to new market entrants. Conversely, strict regulations and standards for global affiliation of medical devices as well as high performance and consistency in quality of the devices are some of the factors limiting the growth of the microfluidic device systems market. Manufacturing issues such as surface chemistry and geometrical issues also account for the challenges faced by the microfluidic device systems market.

The report categorizes the global market for microfluidic device systems chiefly on the basis of four criteria: geography, industry, application, and materials used in the manufacturing process of microfluidic devices.

On the basis of application, the market for microfluidic devices is segmented into pharmaceutical and life sciences research, point of care testing, environment and industrial, clinical and veterinary diagnostics, and drug delivery. Of these, the largest segment of the microfluidic devices market is the veterinary and clinical diagnostic application segment.

Request free Sample pages of premium Research Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1561

Geographically, the microfluidic devices market is segmented into Asia, North America and Europe, wherein North America dominates the global microfluidic devices market, while Asia is a rapidly developing region for the microfluidic devices market.

On the basis of industry, the microfluidic devices market is segmented into in- vitro diagnostics, pharmaceuticals, and medical devices. Among these, in-vitro diagnostics is the largest industry and is estimated to reach US$3.3 bn in 2019.

The report profiles some of the prominent companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Becton Dickinson and Company, Agilent Technologies, Fluidigm Corporation, Bio-Rad Laboratories, and Johnson & Johnson, which are key players in the microfluidic devices market.

The market for microfluidics devices can be expected to rise as microfluidics is an evolving field with a huge potential commercially. With applications in various fields such as cell biology research, protein crystallization, and medicine, microfluidics will remain in the market due to its efficacy in the field of treatment.

Selective Serotonin Reuptake Inhibitors Market size and Key Trends in terms of volume and value 2016-2024

Selective Serotonin Reuptake Inhibitors Market: Overview

Selective serotonin reuptake inhibitors (SSRIs) elevate the extracellular level of neurotransmitters known as serotonin by inhibiting its uptake in presynaptic cells. Therefore, selective serotonin reuptake inhibitors are widely used as medication for the treatment of severe or persistent depression. In addition, selective serotonin reuptake inhibitors are also used in combination with therapies such as cognitive behavioral therapy (CBT).

Furthermore, selective serotonin reuptake inhibitors are also used for mental conditions such as panic disorders, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), severe phobias, including social phobia and agoraphobia, and generalized anxiety disorder (GAD). In addition, selective serotonin reuptake inhibitors are also used for the treatment of premenstrual syndrome, premature ejaculation, irritable bowel syndrome and fibromyalgia. Side effects of selective serotonin reuptake inhibitors include, low sex drive, dizziness, sickness, anxiety, erectile dysfunction in male population and blurred vision.

Selective Serotonin Reuptake Inhibitors Market: Growth Enablers

According to the World Health Organization (WHO), depression is the fourth leading cause of deaths and by 2020; it is expected to be the second leading cause of deaths worldwide. According to the National Institute of Mental Health (NIHM), part of National Institute of Health (NIH) of the U.S., in 2012, around 16 million adults above 18 years of age had at least one major depressive episode in the past year in the U.S. Risk of depression is twice in women population.

According to the Depression and Bipolar Support Alliance, the lifetime prevalence for female population is 20% to 26%. While life time prevalence of depression for male population is 8% to 12%. According to the article published by the British Psychology Society in June 2013, finding from the Office for National Statistics (ONS) states that approximately one fifth of the overall adult population experience depression. Thus, perpetually rising prevalence depression worldwide is the major factor driving the growth of the global selective serotonin reuptake inhibitors (SSRIs) market.

Selective Serotonin Reuptake Inhibitors Market: Region-wise Insight

Geographically, the selective serotonin reuptake inhibitors market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). Presently, Europe and North America are dominating the global selective serotonin reuptake inhibitors (SSRIs) market. Factors such as, divorce, unemployment, work pressure, and higher life expectations are resulting in higher rate of depression cases.

Furthermore, availability of advanced healthcare facilities and higher healthcare spending are driving the growth of selective serotonin reuptake inhibitors market in Europe and North America. Asia Pacific is a lucrative market for selective serotonin reuptake inhibitors (SSRIs). Factors such as rapidly growing prevalence of depression and mental conditions, rising awareness about depression and related treatments available and rising healthcare expenditure are expected to drive the selective serotonin reuptake inhibitors market in Asia Pacific region.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13343

Though, prevalence rate of depression is high in Rest of the World (RoW), lack of awareness about related treatment is limiting the growth of the selective serotonin reuptake inhibitors market in this region. Brazil and Argentina are expected to show faster growth rate than other countries in Rest of the World owing to availability of well defined regulatory framework and developed healthcare infrastructure. African countries will experience slower growth rate in the forecast period due to poorly developed healthcare infrastructure coupled with lack of availability of regulatory framework.

Some of the commercially available brands of SSRI include Fluvoxamine (Luvox), Citalopram (Celexa), Fluoxetine (Prozac), Paroxetine (Paxil), and Sertraline (Zoloft).

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Global Healthcare Contract Research Outsourcing Market to Reach US$65.03 bn by 2018, Globalization of Drug Development to Fuel Demand

Transparency Market Research (TMR) has recently published a report on the global healthcare contract research outsourcing (CRO) market. According to the report, the market is likely to register a remarkable CACR of 14.70% during the period from 2012 and 2018.The research study, titled “Healthcare Contract Research Outsourcing Market - Global Industry Analysis, Size, Share, Trends And Forecast 2012 - 2018,” projects this market to rise from a total value of US$25.08 bn in 2011 to an estimated value of US$65.03 bn by the end of the forecast period.

Contract research outsourcing (CRO) is one of the emerging trends in the global healthcare industry. It involves outsourcing of various research activities, previously performed by the manufacturer, to a third-party. A number of drugmakers and companies operating in the pharmaceutical, biotechnology, and medical devices sectors are nowadays outsourcing research activities to contract researchers in order to reduce manufacturing cost without compromising on the quality of the product.

According to the report, the high cost and a great deal of time involved in healthcare research are encouraging enterprises to partner with CROs thus driving the growth of the worldwide healthcare CRO market significantly. In addition to this, the globalization of drug development is likely to provide a substantial boost to this market during the forecast period.

This report has been prepared by analyzing the global market for healthcare CRO on the basis of service, destination research group, and the region. Based on the service, the market has been classified into regulatory services, clinical trial services, and clinical data management services, and medical writing services. Among these, the clinical trial outsourcing service segment dominated the overall market in 2010, attaining a total value of US$14.2 bn. Drug discovery, preclinical, phase I trial, phase II trial, phase III trial, and phase IV trial have been identified as the key sub-segments of the clinical trial services segment in this research study.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=800

Based on destination research group, the global healthcare CRO market has been categorized into contract research organizations, academic medical centers, and clinical trial laboratories.

The report regionally segments the global healthcare CRO market into North America, Asia, Europe, and the Rest of the World. In 2011, North America led the global market with a whopping share of 64.1% and was closely followed by Europe and Asia. Over the forecast period, the Asia healthcare CRO market is likely to register a significant rise owing to the increasing number of contract research organizations in this region, states the research study.

The competitive landscape prevailing in the global healthcare CRO market has also been analyzed in this research report. According to it, the major players functional in this market are Piramal Life Sciences, Inventiv Health Inc., Medidata Solutions Inc., Icon Plc., Charles River Laboratories International Inc., Parexel International Corp., Pharmaceutical Product Development Inc., Covance Inc., and Quintiles Transnational Corp.

Global Sports Medicine Devices Market to Reach US$8.28 bn by 2019 with Sports Injuries on the Rise

The global sports medicine devices market is progressing at a CAGR of 4.4% within a forecast period of 2013 to 2019. This market was recorded at US$6.1 bn in 2012 and is expected to reach US$8.28 bn by the end of 2019, according to leading market intelligence company, Transparency Market Research.The research report released by TMR, titled “Sports Medicine Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” perfectly encapsulates the critical factors responsible for the growth of this market. The report considers present age facts and augments them according to expected market trends in order to reach the given market predictions for 2019.

According to the report, the main driver for the growth of the global sports medicine devices market is the increasing count of sports injuries occurring around the world. This is caused by the proliferation of sports equipment, apparel, and facilities into the consumer markets, allowing a greater number of people to participate in sporting activities. People from different ages are increasingly becoming a part of sporting clubs or taking up physical activities due to the promotion of fitness products and apparel.

Other reasons for the growth of the global sports medicine devices market include the increasing attention paid to making treatment as cost-effective as possible, the growing percentage of the geriatric demographic, and the increasing disposable income among people.

However, the global sports medicine devices market is currently hindered by the unfavorable medical insurance coverage of sports-related injuries in developed economies.

The two major segments of the global sports medicine devices market are orthopedic products, and recovery and support products.

Orthopedic products are further divided into orthobiologics, prosthesis, fracture repair devices, arthroscopy devices, and artificial joint implants. In 2012, the worth of arthroscopy devices was close to US$1.59 bn, and this segment is progressing at a high CAGR of 5.8% from 2013 to 2019. Conversely, the slowest growth rate was attributed to the segments of prosthesis and accessories.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=765

The report divides recovery and support products into performance monitoring devices, braces, recovery accessories, and other devices.

Geographically, the report segments the global sports medicine devices market into four major regions of North America, Europe, Asia Pacific, and the Rest of the World. In 2012, North America led the revenue generation charts in the global sports medicine devices market, with a net worth of US$2.48 bn. Investors and major players are currently looking to the developing economies of Asia Pacific and the Rest of the World, as these regions are showing promise of a rapidly expanding sports industry.

The key players in the global sports medicine devices market are Zimmer Holdings, Inc., Wright Medical Technology, Inc., Stryker Corporation, Smith & Nephew PLC, Skins International Trading AG, OttoBock Healthcare GmbH, Ossur hf, Mueller Sports Medicine, Inc., DJO Global, Inc., DePuy Mitek, Inc., Conmed Corporation, BREG, Inc., Biomet, Inc., ArthroCare Corporation, Arthrex, Inc., and 3M Company Ace Brand.

New Trends of Endoscopy Devices Market with Worldwide Industry Analysis to 2019

Besides being highly consolidated, the global endoscopy devices market exhibits cutthroat competition among the key players. The three top players dominating the market are Covidien, Ethicon, and Olympus. Together these companies held over 48% of the market based on value, in 2012, states Transparency Market Research (TMR) in a new study. These players are primarily focusing on inorganic activities such as mergers and acquisitions, creating brand loyalty among doctors, and consistent product launches across the product portfolio, which leave limited scope for the entry of new players.

Despite the prevailing competitive landscape, TMR forecasts the global endoscopy devices market to report a CAGR of 6.8% between 2013 and 2019. The market was valued at US$24.9 bn in 2012, and is expected to reach US$36.89 bn by the end of 2019. Regionally, the market is currently led by North America and Europe. However, robust economic development witnessed across its emerging economies will enable the Asia Pacific market for endoscopy devices to grow at a strong CAGR of 7.6% between 2013 and 2019.

Endoscopes, operative devices, and visualization systems are the key product types in the market. Of these, visualization systems led the market in 2012; the segment is expected to reach US$20.6 bn by the end of 2019.

Entry of Business Conglomerates Fuels Scope for Market’s Development

With the entry of business conglomerates such as Canon, Sony, and Panasonic, the endoscopy market is currently witnessing a considerable rise in investment. These enterprises are keen on mergers and acquisitions to gain a stronghold in the market. For example, in a major buyout, Covidien successfully closed the acquisition of Given Imaging Ltd in 2014. This trend is projected to fuel sales of endoscopy devices through the report’s forecast period.

Likewise, the market is expected to gain from conscious efforts by the U.S. FDA to do away with its long and arduous approval process. “The regulatory agency in the last few years has taken constructive steps to ease the approval process,” said a lead TMR analyst. This would inevitably drive the endoscopy devices market. This could also make reimbursement easier due to the reduced risk of side effects.

Furthermore, the innovation of novel technologies will provide a wider scope for application of endoscopy. Besides this, the rising demand for minimally invasive surgeries and diagnostics will fuel the demand for endoscopy systems.

High Manufacturing Cost Limits Scope for Market’s Expansion in Developing Economies

In the developing countries, manufacturers are facing difficulties due to the high cost of manufacturing endoscopy devices. These devices require highly sophisticated technologies and adequate skills in manufacturing, thereby increasing the overall cost of endoscopic devices and associated accessories.

“The inadequate supply of trained surgeons is also creating bottlenecks for the market,” the TMR report’s author observed. The observation is particularly true in case of developing economies where a lesser number of physicians is inhibiting the market’s growth.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=225

Endoscopy Devices Manufacturers to Capitalize on Opportunities in Asia Pacific

The rising prevalence of chronic ailments is expected to create opportunities for the increased sales of endoscopy devices in the forthcoming years. For instance, the demand for endoscopy in diagnostics is expected to rise in response to the increasing incidence of cancer around the world.

The market is also expected to gain impetus from the lucrative opportunities in Asia Pacific. To capitalize on the same, several leading players are looking to venture into the market. The rising healthcare spending reported across the emerging economies of Asia Pacific, and established research and development facilities in China and India are expected fuel growth opportunities for endoscopy devices manufacturers.

DES Segment Boosts Global Coronary Stents Market to 6.6% CAGR till 2019; Overrides Bare Metal Stents Segment

The global coronary stents market exhibits intense competition with the top four players representing nearly 87% of the overall market. The accelerated research activities to launch new and improved coronary stents is boosting the competitive rivalry among the global players, says Transparency Market Research (TMR) in a new study. The top four companies are Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories Inc., and Terumo Corporation. Other key players influencing the growth of the global coronary stents market are B. Braun Melsungen AG and Biotronik SE & Co. KG.

“The new entrants can establish a presence by devising robust market strategies and reliable products to establish themselves in a market already being dominated by large companies. The global coronary stents market is also characterized by high threat of substitutes and strict regulatory requirements, thereby raising the barriers for new entrants,” states the author of the report. However, increasing opportunities for merger and acquisitions for the development of innovative stents for treating multiple coronary artery diseases will attract new companies to the global coronary stents market.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=23

Rising Prevalence of Coronary Artery Diseases to Drive Sales of Coronary Stents

Globally, cardiovascular diseases (CVDs) cause the highest number of deaths every year. According to the World Health Organization (WHO), nearly 17.5 million people died from CVDs in 2012. Out of these, 7.4 million died as a result of coronary artery diseases (CADs). The growing prevalence of CADs will boost the demand for percutaneous coronary interventions (PCIs), which in turn would increase the uptake of coronary stents. Moreover, the rise in global obesity rates will add to various coronary artery diseases. The WHO also estimates that nearly 23% of overweight and obese individuals suffer from some form of CAD. These trends are likely to bolster the growth of the global coronary stents market.

The advent of innovative and new coronary stents, especially the bio-absorbable ones bodes well for the growth of the global coronary stents market. These technologically advanced stents have minimum or no side effects, thereby promoting their uptake. Another factor driving the growth of the global coronary stents market is the increasing geriatric population worldwide. As aged people are more susceptible to CADs, the need for PCIs among such population is relatively higher, which in turn, will propel growth of the global coronary stents market.

Rejection Rate of Coronary Stents Remains High in Less Developed Regions Owing to High Price and Lack of Reimbursement

The global coronary stents market is generating the better part of its revenue from developed countries, while less developed regions such as MEA are still dependent upon other therapies. This is attributed to the high cost of various coronary stents available. Furthermore, patients from several emerging and less developed markets face shortage of reimbursement policies for these stents. The patients, therefore, switch to alternative methods, thereby adversely affecting the demand for coronary stents. Thus, these factors are negatively influencing the growth of the global coronary stents market.

The rising occurrence of side effects such as in-stent restenosis, thrombosis, and late stent restenosis associated with coronary stents has resulted in the rejection of coronary stenting procedures. This is likely to impede the growth of the global coronary stents market. However, novel technologies are expected to reduce the side effects and will increase penetration of coronary stents in developed as well as emerging markets.

Minimum Side Effects to Facilitate Impressive Growth of Bio-absorbable Stents

The global coronary stents market stood at US$ 9.35 bn and is expected to expand at a 9.5% CAGR between 2013 and 2019, reaching the value of US$ 13.85 bn in 2019. Based on product type, drug eluting stents have wider adoption amongst patients due to their easy availability and reduced side effects. The segment is anticipated to account for a dominant 69.5% of the global coronary stents market in terms of revenue by 2019. On the flip side, bio-absorbable stents are projected to register noteworthy growth due to the fact that they get completely absorbed into the tissues, thereby causing minimum or zero side effects.

In terms of geography, North America was the leading segment in 2015 and is expected to retain its position until the end of 2019 owing to the increasing obese and aging population in the region. However, Asia Pacific is showing strong growth owing to the increasing purchasing power and continuously developing healthcare infrastructure.

The information presented in this review is based on a Transparency Market Research report, titled, ‘Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019.’

Pediculosis Treatment Market - Worldwide Market Shares, Strategies, and Forecasts 2014 to 2020

Infestation of blood feeding Phthiraptera, an ectoparasitic insect (Louse) is referred as pediculosis. While sucking human blood, lice saliva enters human circulatory system which causes puritus. Lice can survive away from human host for 10 days post which it dies due to starvation. A mature female louse lay 3 to 6 eggs per day. Eggs (Nits) hatch in 8 to 10 days and reach maturity in 13 to 15 days. Mature lice live for 10 days.

Pediculosis spreads through close physical contact, combs, hats, cloths and linens. Scratching due to intense itching at the infected area is a prominent symptom of pediculosis infection. Nits on hair shafts and red lesions on infected site are some other symptoms of pediculosis. Treatment of pediculosis includes occlusive therapy, environmental eradication, and mechanical removal of lice. Based on the louse type, global pediculosis treatment market is segmented as follows:

• Pediculosis Capitis
• Pediculosis Pubis
• Pediculosis Corporis

Pediculosis capitis infect head, pediculosis pubis infect pubic area and pediculosis corporis lay nits in seams and folds of cloths. Pediculosis pubis is also referred as crabs. Prevalence of pediculosis is perpetually increasing globally. In many parts of the U.S., pediculosis infection to head in school children has reached epidemic proportions. Thus, rising prevalence of pediculosis coupled with lack of awareness about personal hygiene are some of the drivers for growth of the global pediculosis treatment market. In addition, increased use of human lice in forensic studies is fueling the growth of the global pediculosis treatment market. While on the other hand, lack of diagnostic tools and condition specific treatment are some of the major factors that are restraining the growth of the global pediculosis treatment market. Based on the treatment, the global pediculosis market is segmented as follows:

• Dimeticone Lotion
• Malathion + Dimeticone Lotion
• Isopropyl Alcohol
• Suffocation-Based Pediculicide
• Petrolatum
• Mercuric Oxide Ointment
• Others

Presently, North America and Europe are leading the global pediculosis treatment market. Factors such as, exceptionally developed healthcare infrastructure, higher healthcare spending, reimbursement coverage and government support are driving the pediculosis market in North America and Europe. Asia Pacific is a lucrative market for pediculosis treatment. Factors such as rapidly developing healthcare infrastructure on the grounds of growing medical tourism industry, increasing awareness about pediculosis and related treatments, and rising literacy rate are fueling the growth of pediculosis treatment market in Asia Pacific region. India and China account for the largest population pool in the world. Therefore, India and China are anticipated to show fastest growth rate in the forecast period.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3449

In addition to India and China, Japan is also expected to grow at significant growth rate owing to increased focus of Japanese government on improving healthcare facilities in the country. Countries namely, Brazil, Mexico and Argentina in Rest of the World (RoW) are expected to show faster growth rate than rest of the countries in this region owing to availability of well structured regulatory framework and higher rate of awareness about pediculosis. African countries are expected to show slower growth rate in the forecast period owing to poorly developed healthcare infrastructure and poor economy.

Reprocessed Medical Devices Market - Worldwide Market Shares, Strategies, and Forecasts 2014 to 2020

The global market for reprocessed medical devices features a markedly high level of consolidation, with Stryker Sustainability Solutions, Inc. alone holding a share of nearly 62% of the overall market in 2013, reports TMR in a recent market research report. Well-managed supply channels and a strong distribution network have allowed the company to take a coveted spot in the global reprocessed medical devices market.

Owing to the prominence of a few vendors in the market, entry barriers for new vendors are high. Along with the dominance of a very small number of companies, factors such as the requirement of a steady supply of used medical devices, regulatory control exercised by several supervisory bodies, and the necessity of strong distribution networks are challenging new vendors in the global reprocessed medical devices market. However, developing economies, with vast growth opportunities and a highly unorganized reprocessing industry could allow easy admittance to new vendors. Some more of the market’s notable participants are Hygia Health Services, Inc., Centurion Medical Products Corporation, Medline ReNewal, SterilMed, Inc., and SureTek Medical.

The global reprocessed medical devices market is expected to exhibit an exceptional 19.3% CAGR by revenue over the period between 2014 and 2020. The market had a revenue-wise valuation of US$898.7 mn in 2015. In terms of volume, the global market is expected to rise to 56.04 mn by 2020.

Rising Pressure on Reducing Medical Waste and Demand for Reducing Medical Costs Drive Market

That using reprocessed medical devices could help healthcare facilities in saving big bucks is not a difficult guess. The Association of Medical Device Reprocessors (AMDR) states that any typical hospital could save anywhere between US$500,000 to US$2 mn a year using reprocessed medical devices. What’s more, orthopedic surgery centers could save up to US$20,000 per operating room a year by employing reprocessed medical devices. Such vast savings are the chief factor that reprocessed medical devices appeal to healthcare industries across the globe, no matter how strong or weak the economy of a country.

In developed economies, the rising demand to bring down healthcare expenses along with the several regulations requiring proper disposal or reuse of medical devices with a view of reducing the volumes of medical waste are working in favor of the medical devices reprocessing industry. In developing and under-developed economies, on the other hand, the potential of reprocessed medical devices in bridging the gap between the vast demands for healthcare facilities and their absence, especially in remote areas, could allow the global reprocessed medical devices market achieve traction.

Reluctance in Adopting Used Products in Developed Economies and Preference for In-house Reprocessing in Emerging Ones Hinder Market’s Growth

In certain developed countries such as the U.K. and France, healthcare providers and surgical centers are highly reluctant regarding the use of reprocessed medical devices. The lack of awareness and negative perception about the safety, product quality, and efficacy of reprocessed medical devices are key to the low adoption of reprocessed medical devices in such regions.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2064

In developing countries, such as India, China, Singapore, and many other countries in the Middle East, Africa, and Asia Pacific, the large-scale adoption of professionally reprocessed medical devices is hindered due to the high preference for in-house reprocessing.

The lack of specific regulatory guidelines governing the process of medical device reprocessing has helped flourish the intake of easily and economically reprocessed medical devices recovered through in-house processing. This factor is expected to emerge as a key challenge to the overall development of the global reprocessed medical devices market in emerging economies in the next few years.

Cardiovascular Devices Take the Lead

The segment of cardiovascular devices saw the most traction, with 13.69 mn devices reprocessed and/or sold globally in 2015. In terms of revenue as well, the segment of reprocessed cardiovascular devices held the dominant position, with a valuation of US$599.3 mn in the same year. Geography-wise, North America emerged as the clear leader in the global reprocessed medical devices market as of 2015.

This review is based on a recent report published by Transparency Market Research, titled “Reprocessed Medical Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”

Brain Infarction - key factors are diabetes, atherosclerosis, obesity, smoking, blood pressure

Cerebral infarction is one of the major types of ischemic stroke; it occurs due to the development of one or more clots in the blood vessels that carry blood to the brain. The objective of therapy in acute ischemic stroke is to protect the tissue in the ischemic penumbra, where the blood flow may have reduced but is sufficient enough to stave off infarction. Many surgical and endovascular procedures have been examined in the treatment of acute ischemic stroke.

According to a recently updated publication in the Translational Stroke Research, Interleukin-1 receptor antagonist (IL-1 RA) has been systematically studied on animals and is quite close to receiving acceptance for therapeutics of ischemic stroke. The study includes the comparison of effects of IL-1 RA in live, whole animals with focal cerebral ischemia with that of control groups. After a thorough analysis of 25 studies, the treatment with IL-1 RA is linked with substantial improvements in treatment outcome for ischemic stroke, whether quantified as improved neurobehavioral outcome or reduced infarct volume.

The fact that the prevalence of brain disorders is on the rise globally is supported by statistics from the U.S. National Heart, Lung, and Blood Institute (NHLBI). According to statistics of the NHLBI, almost 4.6 million individuals in the U.S. have cardiac stroke disease, which can transform into brain infarction. These factors will translate into promising growth for the global brain infarction market in the future, says a report by Transparency Market Research.

Q. What are the factors driving the growth of the global cerebral infarction market?

A. The increasing prevalence of brain disorders, increasing incidence of diseases that lead to cerebral infarction, increasing awareness about disease treatment, and technological advancements are the major factors driving the growth of the global cerebral infarction market. In addition, extensive R&D practices, wherein a large spectrum of products are in the pipeline is also propelling this market’s growth. These include drugs such as epoetin alfa, CNTO-0007, AP-102, and others.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13232

Q. What is the developmental scenario of the regional cerebral infarction markets?

A. At present, North America and Europe are the key markets for cerebral infarction as these are traditional research-centered regions and have an increasing prevalence of brain diseases. However, Asia Pacific and some developing nations in Rest of the World are anticipated to emerge as significant markets for cerebral infraction. This is due to increased governmental assistance for research into brain disorders and increasing awareness about neurological diseases in these regions

Q. What are the major lines of treatment for cerebral infarction?

A. The major course of treatment for cerebral infarction include thrombolytic drugs and anti-myocardial infarction drugs among others. Some of the thrombolytic drugs which include tissue plasminogen activator (tPA) have proven their efficacy in the management of cerebral infarction. Other than this, the treatment for cerebral infarction includes eliminating the root cause of the condition, which includes blood pressure drugs, diabetes drugs, and others. Carotid endarterectomy is a major surgical treatment for cerebral infarction.

Thus, it can be concluded that extensive research initiatives will lead to even more effectual treatment for cerebral infarction.

Osteosynthesis Devices Market is expected to reach US$11 bn by the end of 2023

Osteosynthesis Devices Market

The key factor responsible for the rising demand for osteosynthesis devices is the growing prevalence of osteoarthritis and osteoporosis. Both medical issues have a considerable public health burden as they occur commonly among the geriatric population around the world. The rise in the number of patients suffering from these conditions is directly related to the growing population of the elderly. Osteoarthritis, termed by major medical organizations as one of the leading disabling diseases in developed countries, can add severe limitations to the movement and mobility of a patient. Therefore, treatment of the disease is pertinent to the overall geriatric demographic wellbeing.

Outside of the elderly population, there are several factors that drastically increase the chances of a patient suffering from osteoarthritis, including obesity and physical injuries. As such, a rise in the number of obese people, especially in developed nations, is a highly concerning factor for healthcare agencies and a major driver for the production and development of osteosynthesis devices. The number of road accidents and sports injuries is also increasing around the world, adding to the probability of an increase in the demand for osteosynthesis devices in the coming years.

Osteosynthesis devices, however, have quite often been subject to product recalls in recent past, severely reducing their overall usability and market growth.

A culmination of the above factors along with other minor drivers and restraints is likely to result in a CAGR of 6.5% for the global osteosynthesis devices market revenue from 2015 to 2023. By the end of 2016, this revenue is expected to reach US$6.69 bn, and US$11.09 bn by the end of 2023.

North America Demand for Osteosynthesis Devices Soars as Elderly Population Increases

By the end of 2023, the revenue generated from North America by manufacturers of osteosynthesis devices is expected to reach US$4.7 bn. This falls in place with the consistent dominance shown by the region in terms of demand. The key reason for this high demand is the large number of geriatrics in the region. Additionally, the large presence of key players and the high investments in osteosynthesis by governments have also added to the growth in demand for osteosynthesis devices in the region. Osteosynthesis devices are mostly available at premium prices in both North America and Europe. This has not deterred purchasers as the use of premium osteosynthesis devices provides a higher level of treatments to be made available for a problem that is already exceedingly high in priority.

Meanwhile, Asia Pacific is showing a significantly high demand for osteosynthesis devices, owing to a high population density and a rapidly increasing healthcare infrastructure and reach. This region’s revenue from osteosynthesis devices is expanding at a CAGR of 8.3% from 2015 to 2023. It is therefore considered as the most lucrative region by key players.

Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5981

Non-degradable Materials Continue Dominating Market Demand

Degradable and non-degradable are the two major types of material categories in use to make osteosynthesis devices. Of these, non-degradable materials already have a long history of use in osteosynthesis devices and orthopedic implants. They are most commonly inclusive of cobalt-chromium alloys, stainless steels, and titanium. At the moment, the overall growth rate and demand for non-degradable osteosynthesis devices is quite high, owing to the utility-based advantages they provide. Titanium, for instance, is considered as the most biocompatible metal and offers high indices of elasticity, strength, and corrosion resistance.

However, non-degradable devices are connected to a higher rate of transmitting infections, thus complicating a patient’s health and increasing the chances for a second surgery. As a result, larger healthcare organizations are pushing for the use of degradable osteosynthesis devices that offer a one-time use and therefore considerably reduce the chances of infections. The future of osteosynthesis devices could very well be based in the development of degradable materials.

The key manufacturers of osteosynthesis devices across the world include DePuy Synthes, Zimmer Biomet, Stryker Corporation, Smith & Nephew, Neosteo SAS, and Aesculap, Inc.

Homeopathic Products Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

A new report by Transparency Market Research presents a complete analysis of driving forces, challenges, trends, and opportunities that will influence the growth trajectory of the homeopathic products market from 2016 to 2024. The title of this report is “Homeopathic Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.” The market study analyzes historical performance and growth trends based on which projections are included. The report analyzes the global homeopathic products market across North America, Asia Pacific, Europe, and Rest of the World for the aforementioned forecast period.

Homeopathy is alternative medicine, which was established in Germany in the later part of the 18^th century. It is based on the idea of ‘Law of Similars’. According to this principle, if a matter can produce symptoms in a healthy individual, it can treat similar symptoms in a sick individual. Homeopathic medicines are composed of natural substances in extremely diluted amounts for the treatment of a number of ailments. These medicines are prepared by repeatedly diluting and vigorous shaking of the original substance preparation in water and alcohol. Post dilution, the medicine is added to pillules or lactose tablets.

The global homeopathic products market is on the rise due to the increasing demand for homeopathy for the treatment of several diseases. According to the World Health Organization, homeopathy is the second largest medicine system displaying a growth rate of 20-25% each year. This is because homeopathy has reportedly proven to be effective for the treatment of several acute and chronic diseases. Though there is a lack of understanding of working of homeopathic medicines, these medicines are believed to be active and are curative.

The increasing participation of several new players is also leading to the growth of the global homeopathy products market. These players are focused on the utilization of new technologies for the development of more effective products.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13049

 North America is the largest regional market for homeopathy products due to several factors. These include increasing preference of individuals for natural and holistic medicine and favorable reimbursement policies for the same. Europe is the second-largest market for homeopathy products. In the U.K., homeopathy is fully recognized as a curative medical practice and is covered by public health insurance. Asia Pacific is emerging as a significant market for homeopathy products due to the rapid advancement of the healthcare industry in emerging economies and the revival of alternative medicine for fewer side-effects. According to a study carried out by the Associated Chambers of Commerce and Industry of India in 2011, the domestic homeopathy market is expected to reach new heights in the coming years.

Some of the leading players in the global homeopathy products market are Hahnemann Laboratories Inc., Natural Health Supply, SBL, Hyland’s Homeopathic, and Nelson & Co. Ltd.

In-store Health Clinics Market - New Business Opportunities & Investment Research Report 2023

A new research report by Transparency Market Research (TMR), titled “In-store Health Clinics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024,” presents a complete overview of this market by analyzing its growth drivers, restraints, market trends, opportunities, and future prospects.

In-store health clinics provide preventive medical care services such as immunization, diagnostic services, physical examination, and lab tests. They also provide medical care such as treatment for illness and injuries, occupational healthcare, physiotherapy to patients with simple sickness.

According to this study, the increased preference among patients for convenient healthcare facilities with a varied range of services has fueled the demand for in-store health clinics significantly across the world. In addition, the low costs of services provided in these clinics are likely to propel their popularity in the coming years.

Geographically, the worldwide market for in-store health clinics has been segmented into North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, and the Middle East and Africa. Currently, North America is leading the global market. The high awareness level regarding healthcare and the increasing propagation of retail clinics is driving the market for in-store health clinics in this region.

In addition, the soaring prevalence of asthma and urinary tract infections, especially in women, is boosting the popularity of these clinics significantly in North America. As per the Centers for Disease Control and Prevention (CDC), around 18 million adults were suffering from asthma in the U.S. in 2012. Various other researches and surveys suggest that more than one million women in the U.S. suffer from urinary tract infections and related complications every year. Both the factors are creating a massive need for medical care, which, in turn, is likely to fuel the demand for in-store health clinics considerably in this region over the coming years.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11531

Other regions, such as South East Asia, the Middle East, and Latin America are also expected to witness a substantial rise in the demand for in-store health clinics in the near future on account of the growing disposable income of people in these regions, notes the research study.

The study identifies the global market for in-store health clinics as highly fragmented in nature, inundated with a number of well-established as well as emerging participants. The leading players, operational in this market, are AFC Doctors Express, Doctors Care, Concentra Inc., FastMed Urgent Care, NEXtCARE, MinuteClinic (CVS), Target Brands Inc., Physicians Urgent Care, The Little Clinic, Urgent Care MSO LLC, U.S. HealthWorks Inc., and Walgreen Co., states the research report.

Recent Trends in Human Microbiome Market

A study on the global human microbiome market by Transparency Market Research (TMR) reports that the increasing incidence of chronic medical conditions such as diabetes, obesity, cancer, cardiovascular diseases, and neurological disorders is the key driving force behind the growing demand for human microbiome across the world. The report, titled “Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” further states that the rising awareness among people regarding the benefits of microbiome products is also adding to the increasing demand for human microbiome. However, strict government regulations pertaining to the usage of microbiome products may perturb the growth trajectory of this market in the coming years.

On the other hand, the continuing advancement in biomedical sciences is likely to create opportunities for the application of human microbiome over the next few years. The increasing interest of leading players in mergers and acquisitions is expected to propel this market signifcanlty during the forecast period, notes the market study.

In this report, the global market for human microbiome has been studied on the basis of disease, product, application, and region. Geographically, the worldwide market for human microbiome has been segmented into Europe, North America, Asia Pacific and the Rest of the World. North America and Europe have been leading the demand for human microbiome over the recent past and are expected to do so during the forecast period.

The continual improvement in the biotechnological and microbiological research infrastructure has been driving the growth of the human microbiome market in these regions since the last few years. Over the coming years, the mounting risk of lifestyle disorders is likely to propel this market in Europe and North America, states the research report.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3999

Based on disease, the report classifies the global market into autoimmune ailments, allergic conditions, diarrhea, obesity, cancer, diabetes, and various other diseases. Based on product, the market has been segmented into probiotics, prebiotics, drugs, devices, and medical foods. Furthermore, the medical food segment has been categorized into oral rehydration products, nutritionally complete formulae, nutritionally incomplete formulae, and formulae for metabolic disorders. Diagnostics and therapeutics have been identified as the two main application areas of human microbiome in this research study.

The leading players in the worldwide human microbiome market are ActoGenix, Enterome Bioscience SA, DuPont, Metabiomics Corp., MicroBiome Therapeutics LLC, Merck & Co. Inc., OptiBiotix Health Plc, Ritter Pharmaceuticals Inc., Osel Inc., Second Genome Inc., ViThera Pharmaceuticals Inc., Vedanta BioScience Inc., and Yakult Honsha Co. Ltd., states the report.

Ebola Drug and Vaccine Market - Worldwide Market Shares, Strategies, and Forecasts 2016 to 2024

The rising threat of a global Ebola pandemic is the major driver for the global Ebola drug and vaccines market, according to a new report from Transparency Market Research. The report, titled ‘Ebola Drug and Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecasts 2016 – 2024,’ presents a solid outline of the historical development of the market, in addition to comprehensive information about the market’s present condition. TMR analysts have further presented reliable predictions regarding the market’s development in the coming years based on insights into the market’s development pattern.

Ebola is a viral disease causing both external and internal bleeding, fever, muscular pain, headaches, vomiting, and notable impairment of liver and kidney functions. Like many viral diseases, Ebola can spread through direct contact with the body fluids of an affected human or animal. The Ebola drug and vaccines market came into the global spotlight after the epidemic in West Africa in late 2013. Since then, governments in many countries where Ebola has spread have taken steps to fund extensive research into treating the disease. Continued government support is crucial for the Ebola drug and vaccines market in the coming years.

The lack of an effective cure for Ebola has driven investment into the field, with the unknown variables about the Ebola virus necessitating extensive research to come up with treatments and disease management plans. This has also made research into Ebola drugs and vaccines financially lucrative for healthcare industry players due to the possibility of coming up with different containment and management solutions targeted at different aspects of the disease.

The government support to the Ebola drug and vaccines market has been amplified by the spread of the disease to the developed world. This has brought the matter to the attention of the much better equipped healthcare sector in the developed world, where long-term research into Ebola therapeutics is economically feasible. This has notably boosted research into the etiology and treatment of the disease in recent years. The prevailing risk of further outbreaks due to the increasing ease of getting in and out of the region where Ebola originated is likely to ensure steady funding for research into Ebola drugs and vaccines in the coming years.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12476

Geographically, North America is the leading contributor to the global Ebola drug and vaccines market. The advanced healthcare research scenario in North America is responsible for the leading share of the regional segment, with U.S. healthcare industry players having among the most comprehensive operations in the field of Ebola research.

The key companies in the global Ebola drug and vaccines market are Serepata Therapeutics, NewLink Genetics Corp., Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., and Mapp Biopharmaceutical. The report presents detailed information about the market operations of these companies in order to derive vital insights into the competitive landscape of the Ebola drug and vaccines market.

Tissue Engineered Skin Substitutes Market - Latest Trends & Insights 2023

The global market for tissue engineered skin substitutes is mostly consolidated as four companies currently maintain a strong hold over revenue shares in market value. The top three players in 2014 were Acelity, Smith & Nephew, and Molnlycke. Their collective share in market value in 2014 was 51.4%. Most commonly, the key providers of tissue engineered skin substitutes offer a wide product profile, invest heavily in research and development to stay ahead of the pack, and possess strong marketing processes and distribution networks.

As a result, although the collective share of regional tissue engineered skin substitute providers is quite large, the reach of key players coupled with the strict set of guidelines governing the release of any product in the market, have created only a moderate threat level from new entrants.

The global market for tissue engineered skin substitutes is expected to generate revenue at a highly positive CAGR of 17.2% within a forecast period from 2015 to 2023. This market is expected to generate a revenue of US$1.2 bn by the end of 2016, and US$3.87 bn by 2023.

Medical Tourism Creates Wide Revenue Stream for Tissue Engineered Skin Substitute Providers

“Medical tourism, as an industry, is already a multi-billion dollar one and is showing an annual growth rate in double digits,” states a TMR analyst. “The use of tissue engineered skin substitutes in developed nations is not only growing in numbers, but is also over-expensive and unaffordable for some without a feasible reimbursement policy. As a result, a large number of patients seeking tissue engineered skin substitute treatment are doing so through medical tourism.”

Nations such as Thailand, Malaysia, India, and Singapore are at the forefront of medical tourism and can offer state of the art technologies for tissue engineered skin substitute treatment at a much cheaper rate than that from North America or Europe.

Additionally, medspas, or medical clinics that include a day spa, are a highly preferred place for treatment and healing by the elderly, especially for cases such as treatment of ulcers and venous diseases. Their higher number in developing economies is another factor driving the scope of medical tourism in the tissue engineered skin substitute market.

Cost Effectiveness of Tissue Engineered Skin Substitutes Reduced by Intense Competition

The presence of a large number of local players adds a major layer of restraint to the globally prominent ones for the tissue engineered skin substitutes market. Local players can offer products at a much cheaper cost, thereby forcing key players to match their prices and reduce profit margins.

The profits that can be channeled into research and development, therefore, decrease, slowing down the overall growth of the market for tissue engineered skin substitutes. This is more prevalent in developing economies, where the disparity in costs between local and global tissue engineered skin substitute players is quite high.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854

Asia Pacific to Scale up Demand for Tissue Engineered Skin Substitutes

Owing to a growing population and a rapidly improving healthcare infrastructure in terms of quality and outreach, Asia Pacific is expected to show the fastest growth rate for tissue engineered skin substitutes. It is expected to progress at a CAGR of 18.3% within the forecast period from 2015 to 2023.

Acellular skin substitutes have not only been the dominant type of tissue engineered skin substitutes, but have registered promising growth. From 2015 to 2023, this segment is expected to progress at a CAGR of 17.8%. The leading application for tissue engineered skin substitutes is to treat ulcers. This application segment is expected to progress at a CAGR of 17.5% from 2015 to 2023.

The information presented in this review is based on a Transparency Market Research report, titled, “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Medical Disposables Market: Industry Players Shifting Focus towards Developing Economies

A new market research report has been recently published by Transparency Market Research, titled “Medical Disposables Market - Global and U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”. According to the research study, in 2011, the global medical disposables market was worth US$144.6 bn and is anticipated to be worth US$193.9 bn by the end of 2018, growing significantly at a 4.30% CAGR between 2012 and 2018.

The research report has provided a detailed analysis of the global medical disposables market, emphasizing on the U.S. market. The report further talks about the market overview, product segmentation, growth drivers, restrains, and vendor analysis. The 50-page research report makes use of graphical representation such as tables and charts to showcase historical data and forecast figures.

Rising demand for healthcare due to the rising global aging population, rising prevalence of chronic conditions that need long-time therapies, and expanding volume of inpatient days and hospital admissions are some of the major factors boosting the demand for medical disposables in the coming years. On the other hand, rigid FDA and GMP approval norms and reduction in the prevalence of healthcare-associated infections are the factors that are expected to curb the growth of this market in the forecast period.

On the basis of product, the global medical disposables market has been segmented into nonwoven medical disposables, wound management disposables, drug delivery disposables, and others (such as laboratory and diagnostic disposables). Furthermore, the market has been classified on the basis of end use into home healthcare facilities, outpatient facilities, emergency care, hospitals, and physician offices. Among these, the hospitals segment is at the forefront of the U.S. medical disposables market. The demand for medical disposables is anticipated to rise in hospitals, thanks to the rising number of patient admissions, surgical procedures, and emergency visits.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=388

The global medical disposables market has been further segmented on the basis of geography into North America, Asia Pacific, Europe, and Rest of the World. Among all these regions, North America exhibited strong demand for all product segments of the market in the recent years. According to the report, the U.S. medical disposables market held around 70% of the North America medical disposables market. In 2011, North America accounted for the largest share of 35% in the global medical disposables market. On the other hand, Asia Pacific is expected to witness rapid growth owing to rising awareness for healthcare. Some of the other factors that are expected to boost the demand for medical disposables in the Asia Pacific market are the huge aging population, increasing disposable income, and rising expenditure by governments on healthcare. The substantial rise of developing nations such as China and India is anticipated to propel the Asia Pacific medical disposables market.

The report also talks about the prominent companies that are operating in the global medical disposables market. The comprehensive analysis includes company overview, product portfolio, business strategies, financial overview, SWOT analysis, and recent developments. Some of the key players are Dickinson, and Company, 3M Company, Becton, Johnson & Johnson, and Covidien plc.